Friday 6 November 2026 Export BDX’s income statement to Excel — free account

Becton, Dickinson and Company

BDX Healthcare Medical Instruments & Supplies

Becton, Dickinson and Company’s revenue for fiscal 2025 (year ended September 2025) was $21.8 billion, up 8.24% from fiscal 2024.

Revenue: −9.55%
EPS: −31.5%
Free cash flow: −31.6%
Total debt: −22.9%

Quarter to June 2026, against a year earlier

212.96 3.77 +1.80%

Follow BDX

Alert me

Market cap: $58.2B
P/E: 64.1×
Fwd P/E: 39.2×
Dividend yield: 1.87%
F-score: 7/9
Altman Z: 1.85
Beneish M: −2.64
Dividend safety: 67/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Becton, Dickinson and Company (BDX) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by segment, and margins
Medical	11,456	52.45%
Interventional	5,217	23.89%
Life Sciences	5,167	23.66%
Gross margin		45.44%
Operating margin		11.80%
Pre-tax margin		8.61%

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011
Medical	11,456 52.45%	10,074 49.93%	9,502 49.05%	8,841 46.85%	8,361 43.70%	7,637 47.51%	9,064 52.42%	8,616 53.91%	7,419 61.35%	7,965 63.81%	6,460 62.83%	4,573 54.14%	4,306 53.46%	4,091 53.07%	4,007 52.83%
Interventional	5,217 23.89%	4,980 24.68%	4,736 24.45%	4,464 23.66%	4,239 22.16%	3,762 23.40%	3,926 22.71%	3,037 19.00%	685 5.66%	689 5.52%	—	—	—	—	—
Life Sciences	5,167 23.66%	5,191 25.73%	5,133 26.50%	5,564 29.49%	6,530 34.13%	4,675 29.08%	4,300 24.87%	4,330 27.09%	3,988 32.98%	3,829 30.67%	3,822 37.17%	3,872 45.84%	3,748 46.54%	—	—
Diagnostics	—	—	—	—	—	—	—	—	—	—	—	—	—	2,538 32.93%	2,480 32.70%
Biosciences	—	—	—	—	—	—	—	—	—	—	—	—	—	1,080 14.01%	1,096 14.45%
Revenue	21,840	20,178	19,372	18,870	19,131	16,074	17,290	15,983	12,093	12,483	10,282	8,446	8,054	7,708	7,584

Operating income by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011
Medical	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Interventional	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Life Sciences	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Corporate and other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Operating income	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
UNITED STATES	12,790 58.56%	11,663 57.80%	11,113 57.37%	10,722 56.82%	10,371 54.21%	9,161 56.99%	8,768 54.86%	6,504 53.78%	6,893 55.22%	5,069 49.30%	3,417 40.46%	3,353 41.63%	3,288 42.66%	3,248 42.83%	3,169 44.48%	—
EMEA	4,729 21.65%	4,402 21.82%	4,244 21.91%	4,043 21.43%	4,548 23.77%	3,734 23.23%	—	—	—	—	—	—	—	—	—	—
Greater Asia	3,093 14.16%	2,906 14.40%	2,913 15.04%	3,047 16.15%	3,069 16.04%	2,384 14.83%	2,460 15.39%	1,744 14.42%	1,692 13.55%	1,545 15.03%	1,437 17.01%	1,344 16.69%	—	—	—	—
Other	1,227 5.62%	1,207 5.98%	1,102 5.69%	1,058 5.61%	1,142 5.97%	794 4.94%	1,457 9.12%	1,257 10.39%	1,225 9.81%	1,234 12.00%	1,210 14.33%	1,168 14.50%	1,159 15.04%	1,113 14.68%	971 13.62%	—
Europe	—	—	—	—	—	—	3,298 20.63%	2,588 21.40%	2,674 21.42%	2,434 23.67%	2,383 28.21%	2,189 27.18%	2,379 30.86%	2,431 32.05%	2,322 32.59%	—
Asia Pacific	—	—	—	—	—	—	—	—	—	—	—	—	883 11.46%	793 10.46%	663 9.31%	—
Segment, Geographical, Groups of Countries, Group One [Member] (Deprecated 2013-01-31)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	3,130 44.80%
Segment, Geographical, Groups of Countries, Group Two [Member] (Deprecated 2013-01-31)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2,408 34.47%
Segment Geographical Groups Of Countries Group Four	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	885 12.66%
Segment Geographical Groups Of Countries Group Three	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	563 8.06%
International	9,049	8,515	8,258	8,148	8,760	6,912	7,215	5,589	—	—	—	—	—	—	—	—
Revenue	21,840	20,178	19,372	18,870	19,131	16,074	15,983	12,093	12,483	10,282	8,446	8,054	7,708	7,584	7,124	6,987

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.